Dana-Farber Cancer Institute: Prostatic Neoplasms trials

The registry lists 57 Prostatic Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 7 are open to participants now and 20 have results posted.

Phase 1 8Phase 2 24Phase 3 4No phase 24(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot FlashesRecruitingNCT07729150Not applicable
• CV CARE: CardioVascular Care in PC PatientsRecruitingNCT06202820Not applicable
• Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE TrialRecruitingNCT06040125Not applicable
• RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeRecruitingNCT05765500Phase 2
• Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation TherapyRecruitingNCT05327465Not applicable
• Serial MRI Scans During Radiation TherapyRecruitingNCT04188535Not applicable
• Stereotactic Magnetic Resonance Guided Radiation TherapyRecruitingNCT04115254Not applicable
• Abemaciclib With or Without Atezolizumab for mCRPCCompletedNCT04751929Phase 2Results posted
• Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedNCT03777982Phase 3Results posted
• Improving Quality of Life of Prostate Cancer Survivors With Androgen DeficiencyCompletedNCT03716739Phase 2Results posted
• Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCCompletedNCT03093428Phase 2Results posted
• A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate CancerTerminatedNCT03093272Phase 2Results posted
• Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyCompletedNCT02903368Phase 2Results posted
• A Selective Androgen Receptor Modulator for Symptom Management in Prostate CancerCompletedNCT02499497Phase 2Results posted
• Incorporating MR Imaging Into Prostate Radiotherapy Treatment PlanningCompletedNCT02470910Not applicableResults posted
• Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateCompletedNCT02268175Phase 2Results posted
• Enzalutamide + External Beam Rt For ProstateCompletedNCT02028988Phase 2Results posted
• Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerCompletedNCT02025010Phase 2Results posted
• Early Changes In Multiparametric MRI In Prostate CancerCompletedNCT01959542Not applicableResults posted
• Study of Enzalutamide in Patients With Castration-resistant Prostate CancerCompletedNCT01942837Phase 2Results posted
• A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate CancerCompletedNCT01858688Not applicableResults posted
• Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate CancerTerminatedNCT00953576Phase 1/2Results posted
• Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local TherapyCompletedNCT00776594Phase 2Results posted
• Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate CancerCompletedNCT00658697Phase 2Results posted
• RAD001 and Bicalutamide for Androgen Independent Prostate CancerCompletedNCT00630344Phase 2Results posted
• The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate CancerCompletedNCT00459186Phase 1/2Results posted
• Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate CancerCompletedNCT00116142Phase 3Results posted
• LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerActive, not recruitingNCT06303713Phase 1
• Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE StudyActive, not recruitingNCT05327452Not applicable
• Video Education With Result Dependent dIsclosureCompletedNCT05225428Not applicable
• TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance)CompletedNCT04936243Not applicable
• Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCActive, not recruitingNCT04846478Phase 1
• RESIST-ADT (Androgen Deprivation Therapy)CompletedNCT04485767Not applicable
• Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersCompletedNCT04330716Not applicable
• Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation TherapyCompletedNCT03761160Not applicable
• Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)CompletedNCT03328091Not applicable
• Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownNCT03141671Phase 2
• Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation TherapyCompletedNCT03070145Not applicable
• Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT02207504Phase 1
• Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care NetworksCompletedNCT01844999Not applicable
• BKM120+Abiraterone Acetate for Metastatic CRPCTerminatedNCT01741753Phase 1
• XL-184+Abiraterone in Post-Chemo CRPCCompletedNCT01574937Phase 1
• Personal Patient Profile Prostate (P4) Randomized, Multisite TrialCompletedNCT00692653Not applicable
• Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or SurgeryTerminatedNCT00458549Not applicable
• Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local TreatmentCompletedNCT00165399Phase 2
• MRI-guided Bone Marrow Biopsies of Prostate Cancer PatientsCompletedNCT00165386Not applicable
• Mifepristone (RU-486) in Androgen Independent Prostate CancerCompletedNCT00140478Phase 2
• Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer PatientsCompletedNCT00139204Not applicable
• Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate CancerCompletedNCT00139191Not applicable
• Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate CancerCompletedNCT00136487Phase 2/3
• A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate CancerCompletedNCT00134706Phase 2
• Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate CancerCompletedNCT00134654Phase 2
• Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate CancerCompletedNCT00116220Phase 3
• Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal BleedingCompletedNCT00114985Phase 2
• Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00005627Phase 1
• Docetaxel in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00005096Phase 2
• Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate CancerCompletedNCT00003045Not applicable